Has the Australian Biotech Industry valuation changed over the past few years?

Investors are optimistic on the Australian Biotechs industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 55.4x which is higher than its 3-year average PE of 41.6x. The 3-year average PS ratio of 5.4x is higher than the industry's current PS ratio of 3.4x.

Which industries have driven the changes within the Australian Healthcare industry?

There are no additional sub-industries under this industry.

Australian (ASX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 18 Aug 2026	AU$78.1b	AU$23.2b	AU$1.4b	24x	55.4x	3.4x
Thu, 16 Jul 2026	AU$71.5b	AU$23.6b	AU$1.4b	22.3x	49.5x	3x
Sat, 13 Jun 2026	AU$63.2b	AU$23.4b	AU$1.4b	20.1x	44.1x	2.7x
Mon, 11 May 2026	AU$69.9b	AU$22.8b	AU$1.4b	22.4x	50.8x	3.1x
Wed, 08 Apr 2026	AU$78.3b	AU$23.8b	AU$1.5b	23.7x	53.7x	3.3x
Fri, 06 Mar 2026	AU$81.5b	AU$23.4b	AU$1.4b	25.6x	57.1x	3.5x
Sun, 01 Feb 2026	AU$98.8b	AU$23.6b	AU$3.8b	20.3x	25.7x	4.2x
Tue, 30 Dec 2025	AU$96.3b	AU$24.5b	AU$4.0b	18.7x	24x	3.9x
Thu, 27 Nov 2025	AU$101.4b	AU$25.3b	AU$4.1b	19.1x	24.4x	4x
Sat, 25 Oct 2025	AU$116.1b	AU$25.3b	AU$4.1b	22.2x	28x	4.6x
Mon, 22 Sep 2025	AU$108.1b	AU$24.9b	AU$4.1b	21.1x	26.5x	4.3x
Wed, 20 Aug 2025	AU$121.7b	AU$25.0b	AU$4.3b	35.6x	28.5x	4.9x
Fri, 18 Jul 2025	AU$134.5b	AU$24.6b	AU$3.9b	39.4x	34.6x	5.5x
Sun, 15 Jun 2025	AU$129.5b	AU$24.5b	AU$3.9b	20x	33.4x	5.3x
Tue, 13 May 2025	AU$127.7b	AU$24.9b	AU$3.9b	20.3x	32.4x	5.1x
Thu, 10 Apr 2025	AU$126.2b	AU$26.2b	AU$4.2b	18.9x	30.3x	4.8x
Sat, 08 Mar 2025	AU$140.6b	AU$25.2b	AU$4.0b	22x	35.2x	5.6x
Mon, 03 Feb 2025	AU$153.4b	AU$24.7b	AU$3.7b	24.4x	41.4x	6.2x
Wed, 01 Jan 2025	AU$151.8b	AU$24.7b	AU$3.7b	24.5x	41x	6.1x
Fri, 29 Nov 2024	AU$151.8b	AU$23.7b	AU$3.5b	26.2x	43.1x	6.4x
Sun, 27 Oct 2024	AU$154.4b	AU$23.3b	AU$3.5b	27.9x	44.6x	6.6x
Tue, 24 Sep 2024	AU$153.7b	AU$22.6b	AU$3.3b	28.4x	46x	6.8x
Thu, 22 Aug 2024	AU$160.2b	AU$22.8b	AU$3.5b	30.3x	46.4x	7x
Sat, 20 Jul 2024	AU$162.1b	AU$22.0b	AU$3.2b	33.3x	50.1x	7.4x
Mon, 17 Jun 2024	AU$150.5b	AU$22.3b	AU$3.3b	31x	46x	6.8x
Wed, 15 May 2024	AU$144.8b	AU$22.2b	AU$3.3b	31x	44.6x	6.5x
Fri, 12 Apr 2024	AU$144.2b	AU$22.5b	AU$3.3b	30.6x	43.7x	6.4x
Sun, 10 Mar 2024	AU$145.5b	AU$22.2b	AU$3.2b	29.6x	44.8x	6.6x
Tue, 06 Feb 2024	AU$152.4b	AU$21.1b	AU$2.9b	34.4x	53.1x	7.2x
Thu, 04 Jan 2024	AU$144.8b	AU$20.4b	AU$2.7b	34.1x	53.7x	7.1x
Sat, 02 Dec 2023	AU$134.2b	AU$20.7b	AU$2.7b	33.7x	48.8x	6.5x
Mon, 30 Oct 2023	AU$119.1b	AU$21.6b	AU$2.9b	28.7x	41.1x	5.5x
Wed, 27 Sep 2023	AU$130.8b	AU$21.5b	AU$2.8b	30x	46.5x	6.1x
Fri, 25 Aug 2023	AU$135.2b	AU$21.3b	AU$2.6b	38.6x	52.2x	6.3x


AU Market	-1.48%
Healthcare	0.29%
Biotech	0.16%
Biotech	0.16%

Company	Last Price	7D	1Y	Valuation
CSL CSL	AU$157.82	14.1% +AU$9.3b	-30.0%	PS3.4x
CUV Clinuvel Pharmaceuticals	AU$10.36	6.7% +AU$32.8m	-15.6%	PE16.1x
DXB Dimerix	AU$0.29	3.5% +AU$6.0m	-37.2%	PS23.9x
IMM Immutep	AU$0.053	6.0% +AU$4.4m	-79.6%	PS9.9x
RAC Racura Oncology	AU$2.12	1.0% +AU$3.9m	70.3%	PS119.2x

Announcement • Jul 06

Immuron Advances Imm-529 Partnering Strategy and Provides Updates on Clinical Development

Immuron Limited engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529. Pullan Consulting specializes in guiding biotechnology and pharmaceutical companies through the partnering process, from strategy development and partner identification to negotiation and transaction execution. Immuron has U.S. Food and Drug administration approval for IMM-529 Investigational New Drug application (IND 32095) for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection in a Phase 2 clinical trial. IMM-529 has a validated biological target. FDA-approved monoclonal antibody Bezlotoxumab was developed as a first-in-class therapy designed to prevent recurrence of Clostridioides difficile infection by neutralizing toxin B, the major driver of recurrent disease. IMM-529’s polyclonal antibodies offer multivalent defense compared with monoclonal single-epitope antibodies. IMM-529 also has an advantage over current standard of care antibiotic treatments that disrupt microbiota. IMM-529 decolonizes the gut facilitating clearance of the pathogen, recovery of the microbiome and prevention of recurrent infection. Immuron has completed an Investigational Brochure and clinical protocol and has secured a principal investigator and three Australian sites. This trial is eligible for Australia’s Clinical Trial Notification scheme, a fast-track method for initiating trials. Immuron has manufactured and released drug product for supply of a clinical trial. The trial protocol is for a randomized, double blind, placebo-controlled clinical study of IMM-529 with Standard of Care for the treatment of Clostridioides difficile infection in subjects with first episode Clostridioides difficile infection or recurrent Clostridioides difficile infection. Up to 60 subjects will be enrolled in the study. Subjects would be randomly assigned to IMM-529 plus Standard of Care or placebo plus Standard of Care in a 2:1 ratio at multiple sites. The primary objective would be to evaluate the safety and tolerability of IMM-529 together with Standard of Care in patients with Clostridioides difficile infection or recurrent Clostridioides difficile infection. Determination of efficacy would be assessed by the measurement and comparison of mortality rate, disease symptoms and recurrence rate for each treatment group. Opportunity assessment by Lumanity indicates that if efficacious, IMM-529 will be positioned as early in treatment algorithm as payers will allow. It is anticipated that first-episode and recurrent patients will be recruited in the IMM-529 Phase 2 clinical trial design. Up to 98,000 patients would be eligible if IMM-529 is positioned at the first recurrence. Based on the estimated market size, anticipated payer restrictions, pricing, and competition, base case yearly revenue for IMM-529 is projected at USD 400 million. Oral dosing of IMM-529 was viewed as a positive by infectious disease experts. The Company is seeking partners to advance clinical development of IMM-529. Under a licensing model, the licensee typically funds development, registration, and commercialization costs. Common licensing agreements include upfront fees upon execution of the document, as well as developmental milestone payments and royalties on product sales. Terms from select historical Clostridioides difficile infection-focused deals that show a range of possible transaction structures are shown below. With upfront payments ranging from USD 1 million to USD 50 million, milestone payments ranging from USD 25 million to USD 570 million, and typical royalties on sales in the mid-to-high single digit percentage range, a successful development partnership for its IMM-529 asset could prove transformational for Immuron. Destiny Pharma licensed NTCD-M3 (nontoxigenic Clostridioides difficile strain, live biotherapeutic) to Sebela Pharmaceuticals with upfront USD 1 million; up to USD 570 million milestones (including USD 19 million development and up to USD 550 million sales) plus royalties. Summit Therapeutics licensed Ridinilazole (small molecule antibiotic) to Eurofarma with USD 2.5 million upfront; up to USD 25 million milestones plus royalties. Assembly Biosciences licensed Microbiome GI programs to Allergan (later AbbVie) with USD 50 million upfront plus milestones and royalties. The increased incidence of antibiotic resistant ‘superbugs’ has amplified the use of broad-spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of the gastrointestinal microbiota, resulting in susceptibility to opportunistic pathogens, such as Clostridioides difficile. Treatment of Clostridioides difficile infection also involves antibiotic use, and the heavy reliance on antibiotics to control Clostridioides difficile does not allow for the gut flora to regenerate and predisposes the patient to relapsing Clostridioides difficile infection. Clostridioides difficile is currently the most common pathogen in healthcare-associated infections and was deemed an urgent threat in the Center for Disease Control and Prevention’s report on antibiotic resistance threats in the United States. Clostridioides difficile infection affects over 400,000 people in the US on a yearly basis, contributing to over 30,000 deaths in the US alone annually. Immuron collaborated with Dr. Dena Lyras and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate hyperimmune bovine colostrum that contains antibodies targeting three essential Clostridioides difficile virulence components. IMM-529 targets Toxin B, the spores, and the surface layer proteins of the vegetative cells. This unique 3-target approach has yielded promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence (67%, P). Immuron’s proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and the products are orally active. Bovine immunoglobulins can withstand the acidic environment of the stomach and are resistant to proteolysis by the digestive enzymes found in the Gastrointestinal tract. Bovine immunoglobulins also possess this unique ability to remain active in the human Gastrointestinal tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.

Australian (ASX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Full year 2026 earnings released: US$5.35 loss per share (vs US$6.20 profit in FY 2025)

Mesoblast Limited Completes Patient Treatment In Pivotal Phase 3 Trial Of Rexlemestrocel-L For Chronic Low Back Pain

Price target increased by 44% to AU$3.28

Amplia Therapeutics Limited Details Preclinical Studies of Narmafotinib In Pancreatic Cancer

Telix Pharmaceuticals Limited to Report First Half, 2026 Results on Aug 20, 2026

Radiopharm Theranostics Limited has completed a Follow-on Equity Offering in the amount of $4.050001 million.

Clinuvel Pharmaceuticals Ltd Provides Update On SCENESSE In Vitiligo

Price target increased by 7.9% to AU$6.60

Aroa Biosurgery Limited Appoints Michael Lynskey as Chief Commercial Officer and A Member of the Executive Leadership Team

Actinogen Medical Announces Results from Xanamem Phase 2 Depression Proof-Of-Concept Trial

Immutep Limited Provides Positive Update on INSIGHT-003 Phase I Trial and Discontinues TACTI-004 Phase III Trialin 1 Line Non-Small Cell Lung Cancer

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Immuron Advances Imm-529 Partnering Strategy and Provides Updates on Clinical Development

New major risk - Share price stability

Racura Oncology Doses First Patient in Harness-1 Phase 1A/B Trial of Rc220 in Combination with Osimertinib for Egfr-Mutant Non-Small Cell Lung Cancer

We're Hopeful That Nexsen (ASX:NXN) Will Use Its Cash Wisely